A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc.
University of California, Irvine
M.D. Anderson Cancer Center
Astellas Pharma Inc
Arcus Biosciences, Inc.
R-Pharm
BeOne Medicines
Janssen Research & Development, LLC
H. Lee Moffitt Cancer Center and Research Institute
Wake Forest University Health Sciences
Kyowa Kirin Co., Ltd.
Oscotec Inc.
Gilead Sciences
Instituto do Cancer do Estado de São Paulo
AbbVie
InSilico Medicine Hong Kong Limited
Fate Therapeutics
University of Iowa
AstraZeneca
Jonsson Comprehensive Cancer Center
IDEAYA Biosciences
BioNTech SE
University of Southern California
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Tesaro, Inc.
Amgen
Tufts Medical Center
University of Chicago
Memorial Sloan Kettering Cancer Center
Emory University
Memgen, Inc.
Sumitomo Pharma America, Inc.
Trishula Therapeutics, Inc.
AbbVie
Jiangsu Hansoh Pharmaceutical Co., Ltd.
National Cancer Center, Japan
Weill Medical College of Cornell University
Thomas Jefferson University
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Hummingbird Bioscience
Qilu Pharmaceutical (Hainan) Co., Ltd.
IGM Biosciences, Inc.
Amgen
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Boehringer Ingelheim
Ohio State University Comprehensive Cancer Center
Pfizer
GlaxoSmithKline